title: Epstein Barr virus-induced hepatitis associated with methotrexate treatment.
authors.forename: Marie-George
authors.initials: MG
authors.lastname: Lapalus
authors.forename: Arnaud
authors.initials: A
authors.lastname: Hot
authors.forename: Aurélie
authors.initials: A
authors.lastname: Fontana
authors.forename: Olivier
authors.initials: O
authors.lastname: Guillaud
authors.forename: Pierre
authors.initials: P
authors.lastname: Miossec
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Scoazec
authors.forename: Jérôme
authors.initials: J
authors.lastname: Dumortier
mesh_terms: D056486:Chemical and Drug Induced Liver Injury / Q000175:diagnosis*; D003937:Diagnosis, Differential; D020031:Epstein-Barr Virus Infections / Q000175:diagnosis* / Q000276:immunology; D005260:Female; D006525:Hepatitis, Viral, Human / Q000175:diagnosis* / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D008111:Liver Function Tests; D008178:Lupus Erythematosus, Cutaneous / Q000188:drug therapy; D008727:Methotrexate / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D012698:Serologic Tests
chemical_list: D007166:Immunosuppressive Agents; D008727:Methotrexate